PCSK9 in Familial Hypercholesterolemia and Beyond

This Viewpoint explores the discovery of PCSK9 inhibitors and discusses their role in the treatment of familial hypercholesterolemia.

Read the full article here

Source: jamanetwork.com

Categories: General Medicine News

Tweets with this article

JAMA Cardiology

Viewpoint: The discovery of PCSK9's role in familial hypercholesterolemia has led to the development of effective PCSK9 inhibitors that lower LDL cholesterol and improve cardiovascular outcomes. https://t.co/OBDVgR8nqN

Conjunctival Melanoma With Invasion of a LASIK Flap Interface

This case report describes invasion of a laser-assisted in situ keratomileusis (LASIK) flap interface by conjunctival malignant melanoma in a male patient aged 71 years.

JAMAOphthalmology June 9, 2025

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults

This double-blind, placebo-controlled randomized clinical trial determines the safety and efficacy of repeated low doses of lysergic acid diethylamide (LSD) in reducing attention-deficit/hyperactivity disorder (ADHD)…

JAMA Psychiatry June 9, 2025

Mohs Surgery vs Wide Local Excision in Primary High-Stage Cutaneous Squamous Cell Carcinoma

This cohort study assesses the outcomes of primary high-stage cutaneous squamous cell carcinoma among patients treated with Mohs surgery compared with those treated with wide…

JAMA Dermatology June 9, 2025

Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity

This study compares clopidogrel vs aspirin monotherapy in patients with high bleeding risk and/or percutaneous coronary intervention complexity.

JAMA Cardiology June 9, 2025

Immune Checkpoint Inhibitors for Patients With Autoimmune Neurologic Disorders

This cohort study evaluates the safety and clinical outcomes of immune checkpoint inhibitor therapy among patients with neurologic autoimmune disorders, including multiple sclerosis, myasthenia gravis,…